Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors

NCT04478279 is registered in ClinicalTrials.gov with Sapience Therapeutics as lead sponsor.

NCT NCT04478279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04478279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
Lead sponsor
Sapience Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 1, 2020
Completion date
December 31, 2026
Enrollment
125 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, breast cancer, gbm, glioblastoma, glioblastoma multiforme, melanoma recurrent, melanoma stage iv, metastatic breast cancer, metastatic melanoma, metastatic prostate cancer, newly diagnosed glioblastoma, prostate cancer, prostate cancer metastatic, recurrent glioblastoma